In the chaos of Jefferies Healthcare Conference, I caught up with Ali Pashazadeh, CEO of Treehill Partners - a specialist advisory firm transforming the life sciences - to find out why:
- 50% of Phase III drugs fail (and how 75% of those failures could be avoided)
- Biotech execs think in verticals, when they should be thinking horizontally
- We don't see IPOs from British biotechs
